NAUT
Nautilus Biotechnology, Inc.Company Information
- Company Name
- Nautilus Biotechnology, Inc.
- CIK
- CIK0001808805
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- NAUT: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 08 Industrial Applications and Services
- SIC
- 3826
- SIC Description
- Laboratory Analytical Instruments
- Ticker
- NAUT
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-03-04
- Last sale
- 2026-06-02
- Shares purchased (TTM)
- 132,500
- Shares sold (TTM)
- 5,000,000
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 47,898,249
- Shares outstanding
- 126,634,782
- Ownership
- 37.82%
Earnings Market Reaction
- Filing date
- 2026-04-28
- Price on filing date
- —
- 1-month reaction
- -1.93%
- 3-month reaction
- -32.82%
Balance Sheet
Values in millions ($)| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 15 | 12 | 24 | 34 | 33 | 28 | 4 | 25 | 26 | 19 | 74 | 72 | ||||||
| Available For Sale Securities Debt Securities Current | 81 | 91 | 108 | 113 | 106 | 102 | 136 | 143 | 156 | 154 | 109 | 91 | ||||||
| Prepaid Expense And Other Assets Current | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 3 | 4 | 3 | 3 | 3 | ||||||
| Assets Current | 99 | 106 | 134 | 151 | 142 | 133 | 144 | 171 | 185 | 177 | 187 | 167 | ||||||
| Property Plant And Equipment Net | 4 | 3 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 4 | 4 | 4 | ||||||
| Operating Lease Right Of Use Asset | 27 | 28 | 25 | 26 | 27 | 28 | 29 | 30 | 32 | 33 | 34 | 35 | ||||||
| Long Term Investments | - | - | - | - | - | - | - | - | - | - | 92 | 123 | ||||||
| Available For Sale Securities Debt Securities Noncurrent | 48 | 53 | 37 | 32 | 54 | 76 | 81 | 65 | 66 | 91 | - | - | ||||||
| Other Assets Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | ||||||
| Assets | 178 | 191 | 201 | 213 | 228 | 243 | 260 | 273 | 289 | 306 | 318 | 331 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 1 | ||||||
| Operating Lease Liability Current | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | ||||||
| Liabilities Current | 8 | 8 | 9 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 8 | ||||||
| Operating Lease Liability Noncurrent | 25 | 26 | 23 | 24 | 25 | 26 | 28 | 29 | 30 | 31 | 32 | 33 | ||||||
| Liabilities | 33 | 34 | 32 | 32 | 33 | 34 | 36 | 37 | 39 | 40 | 41 | 41 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 491 | 489 | 487 | 486 | 484 | 482 | 478 | 475 | 471 | 468 | 465 | 461 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | 0 | 0 | 0 | 0 | 0 | 1 | -1 | -1 | -0 | -2 | -2 | ||||||
| Retained Earnings Accumulated Deficit | -347 | -332 | -318 | -305 | -290 | -273 | -255 | -239 | -221 | -202 | -185 | -169 | ||||||
| Stockholders Equity | 144 | 157 | 169 | 181 | 194 | 209 | 223 | 235 | 249 | 265 | 277 | 290 | ||||||
| Liabilities And Stockholders Equity | 178 | 191 | 201 | 213 | 228 | 243 | 260 | 273 | 289 | 306 | 318 | 331 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | ||||||
| Common Stock Shares Issued | 127 | 126 | 126 | 126 | 126 | 126 | 126 | 125 | 125 | 125 | 125 | 125 | ||||||
| Shares Outstanding | 127 | 126 | 126 | 126 | 126 | 126 | 126 | 125 | 125 | 125 | 125 | 125 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialNautilus Biotechnology, Inc. (NAUT) — SEC Financial Statements & Analysis
Nautilus Biotechnology, Inc. (NAUT) is a laboratory analytical instruments company. Nautilus Biotechnology, Inc. trades on Nasdaq as: NAUT. Nautilus Biotechnology, Inc. (NAUT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-04-28. Based on that filing, Nautilus Biotechnology, Inc. carries a market cap of $491.34M, a P/E ratio of -8.61x, a P/B ratio of 3.40x, an enterprise value of $475.71M, and an EV/EBITDA multiple of -7.60x. On profitability, it posts a Return on Equity (ROE) of -33.69%, a Return on Assets (ROA) of -28.16%, and a Return on Invested Capital (ROIC) of -44.41%. Per share, it reports EPS of $-0.45, diluted EPS of $-0.45, free cash flow per share of $-0.41, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -16.86% year-over-year and EPS growth of -17.18% year-over-year. On the balance sheet, it maintains a current ratio of 11.85x, a quick ratio of 11.49x, working capital of $90.49M, a debt-to-equity ratio of 0.23x, a debt ratio of 0.19, an interest coverage ratio of -9.06x, free cash flow of $-51.43M (TTM), and net debt of $-15.63M. Figures sourced from SEC EDGAR.
- Market Cap
- $491.34M
- P/E TTM
- -8.61x
- EPS TTM
- $-0.45
- P/B TTM
- 3.40x
- ROE TTM
- -33.69%
- ROA TTM
- -28.16%
- Debt To Equity
- 0.23x
- Free Cash Flow TTM
- $-51.43M
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Nautilus Biotechnology, Inc. in?
Nautilus Biotechnology, Inc. (NAUT) operates in the Laboratory Analytical Instruments industry.
What exchange does NAUT trade on?
Nautilus Biotechnology, Inc. (NAUT) trades on the Nasdaq.
When was Nautilus Biotechnology, Inc. (NAUT)'s most recent SEC filing?
Nautilus Biotechnology, Inc. (NAUT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-04-28.
What is NAUT's market cap?
Nautilus Biotechnology, Inc. (NAUT) has a market capitalization of $491.34M as of 2026-03-31.
What is NAUT's EPS (earnings per share)?
Nautilus Biotechnology, Inc. (NAUT)'s trailing twelve month EPS is $-0.45 as of 2026-03-31.
What is NAUT's ROE (return on equity)?
Nautilus Biotechnology, Inc. (NAUT)'s trailing twelve month Return on Equity (ROE) is -33.69% as of 2026-03-31.
What is NAUT's ROA (return on assets)?
Nautilus Biotechnology, Inc. (NAUT)'s trailing twelve month Return on Assets (ROA) is -28.16% as of 2026-03-31.
What is NAUT's ROIC (return on invested capital)?
Nautilus Biotechnology, Inc. (NAUT)'s trailing twelve month Return on Invested Capital (ROIC) is -44.41% as of 2026-03-31.
What is NAUT's EV/EBITDA?
Nautilus Biotechnology, Inc. (NAUT)'s trailing twelve month EV/EBITDA is -7.60x as of 2026-03-31.